Cancer vaccine Theratope - Biomira

Drug Profile

Cancer vaccine Theratope - Biomira

Alternative Names: Theratope

Latest Information Update: 31 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomira
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Breast cancer; Colorectal cancer
  • No development reported Adenocarcinoma; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 30 Jul 2004 Theratope® is available for licensing (
  • 30 Jul 2004 Biomira has completed enrolment in a phase II trial for breast cancer in the USA
  • 07 Jun 2004 Merck KGaA has terminated its licence for Theratope®
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top